ATS 2019 Virtual Final Program

1017 Sarcoidosis Vs. Sarcoidosis: A Unique Phenotype in WTC Exposed Survivors/ K. Hena, S. Murphy, Y. Zhang, Y. Shao, J. Reibman, New York, NY, p.A2496 1018 Synergistic Interleukin-1 a Elaboration Due to World Trade Center Particulate Matter and Lipid Co-Exposure In Vitro Is Not NF-kB Dependent/ D. Ostrofsky, R. Lam, S.H. Haider, G. Crowley, A. Talusan, S. Kwon, L. Zhang, M. Liu, A. Nolan, New York, NY, p.A2497 1019 Circulating Mediators of Tissue Remodeling in World Trade Center (WTC) Exposure Community Members with Uncontrolled Lower Respiratory Symptoms/ G. Grunig, N. Durmus, K. Doo, Y. Zhang, Y. Shao, M. Cotrina, J. Reibman, New York, NY, p.A2498 1020 Asthma Phenotypes in World Trade Center Workers: A Cluster Analysis/ J.P. Wisnivesky, B. Rojano, S. Chen, B. Liu, E.G. Federmann, D. Harrison, L. Crowley, A. Federman, S. Markowitz, New York, NY, p.A2499 1021 Air Pollution/Irritants Trigger and Factors Associated with Asthma Control and Quality of Life Among World Trade Center Health Registry Enrollees with Asthma/ J. Yung, S. Osahan, S. Friedman, J. Cone, New York, NY, p.A2500 1022 Comparison of Pulmonary Function in Females Using Clean Fuel and Biomass Fuel in Allahabad District, Uttar Pradesh, India/ T. Mahmood, A.D. Shukla, A.K. Verma, S. Satpathy, Allahabad, India, p.A2501 1023 Airway Oscillometry Identified High Prevalance of Lung Function Abnormalities in Community Members 2 Years After the Alberta Wildfires/ C.-W. Chow, E. deHaas, J. Wu, L. Woo, K. Yang, L. Kohl, A. Chan, Toronto, Canada, p.A7345 CLINICAL POSTER DISCUSSION SESSION A105 GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH 2:15 p.m. - 4:15 p.m. KBHCCD Room C140/C142 (Level 1) Poster Viewing 2:15-3:00 Discussion 3:00-4:15 Chairing: S.M. Kawut, MD, MS, Philadelphia, PA I.M. Lang, PhD, Vienna, Austria G.S. Butrous, MBChB, PhD, Canterbury, United Kingdom 101 The Impact of Time from Diagnosis at Baseline on Long-Term Outcome in the GRIPHON Study: Selexipag in Pulmonary Arterial Hypertension/ S.P. Gaine, O. Sitbon, R.N. Channick, K.M. Chin, L. Di Scala, N. Galiè, M.M. Hoeper, V.V. McLaughlin, R. Preiss, L.J. Rubin, G. Simonneau, V. Tapson, H.A. Ghofrani, I.M. Lang, Dublin, Ireland, p.A2502 102 Risk Assessment at Baseline and One Year in Patients with Pulmonary Arterial Hypertension (PAH): Data from the First 250 Patients Enrolled in SPHERE (Uptravi ® [SelexiPag]: tHe UsErs dRug registry)/ H.W. Farber, M.M. Chakinala, K.B. Highland, V.V. McLaughlin, N.H. Kim, A.R. Hemnes, C. Zhao, J. Colvin, M. Shah, K.M. Chin, Boston, MA, p.A2503 103 A Pragmatic Approach to Risk Assessment in Pulmonary Arterial Hypertension Using the ESC/ERS Guidelines/ A. Manes, F. Dardi, M. Palazzini, E. Gotti, A. Rinaldi, G.V. Lo Russo, E. Zuffa, D. Guarino, A. De Lorenzis, F. Pasca, I. Magnani, M. Rotunno, N. Galié, Bologna, Italy, p.A2504 104 Insights from the Pulmonary Vascular Phenomics Project (PVDOMICS): The Effect of Multiple Pulmonary Vascular Groups on Hemodynamics in Pulmonary Hypertension/ F.P. Rischard, Tucson, AZ, p.A2505 105 Factors Associated with Guideline-Discordant Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension Among US Veterans, 2006-2015/ K.R. Gillmeyer, K.M. Lee, Q. Shao, M.E. Glickman, J.T. Hanlon, D.R. Miller, S.T. Rinne, E.S. Klings, B.A. Maron, R.S. Wiener, Boston, MA, p.A2506 106 The Incremental Shuttle Walking Test Can Be Used to Risk Stratify Patients with Pulmonary Hypertension as Per the European Respiratory/Cardiac Society Guidelines/ R. Lewis, C. Billings, J. Hurdman, I. Smith, M. Austin, I. Armstrong, A. Swift, A. Rothman, A. Charalampopoulos, I. Sabroe, C. Elliot, R. Thompson, A. Lawrie, R. Condliffe, D. Kiely, Sheffield, United Kingdom, p.A2507 107 Obesity Paradox in Pulmonary Hypertension: Insights from a Large Retrospective Cohort Study/ A.W. Trammell, A.P. Shah, L.S. Phillips, C.M. Hart, Atlanta, GA, p.A2508 108 Interim Results from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for the Treatment of Pulmonary Arterial Hypertension/ V.V. McLaughlin, A.D. Ristic, P. Jansa, E.S. Klings, J.A. Barberà, A. Keogh, J. Adams, B. Walsh, J.K. Zhang, C. Cabell, P. Klassen, L. Rubin, Ann Arbor, MI, p.A2509 109 Obesity and Quality of Life in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR)/ J. Min, R.L. Benza, J.P. Feldman, E.B. Rosenzweig, E. Horn, J.S. Sager, K.W. Presberg, O.A. Shlobin, S.C. Mathai, J.W. McConnell, C.D. Burger, R.P. Frantz, J.R. Klinger, C.E. Ventetuolo, M. Eggert, R.T. Zamanian, J. Robinson, M.R. Lammi, T. De Marco, R. Allen, J.M. Elwing, T.M. Bull, D.B. Badesch, T.L. Williamson, G. Ramani, T. Thenappan, H.J. Ford, R. White, J.R. Runo, M. Simon, S. Bartolome, A. Hemmes, D. Grinnan, M.M. Chakinala, S. M. Kawut, N. Al-Naamani, Philadelphia, PA, p.A2510 110 Increased Hepatic Insulin Extraction and Ketogenesis in Idiopathic Pulmonary Arterial Hypertension: A Hyperglycemic Clamp Study/ G.A. Heresi, J. Mey, A. Hari, C. Fealy, R.A. Dweik, J.P. Kirwan, Cleveland, OH, p.A2511 111 Comparison of Risk Discrimination Between the REVEAL 2.0 Calculators, the French Pulmonary Registry Algorithm and the Bologna Method in Patients with Pulmonary Arterial Hypertension (PAH)/ R.L. Benza, M. Kanwar, A. Raina, L.C. Lohmueller, D.J. Pasta, R. La, C.G. Elliott, H.W. Farber, Pittsburgh, PA, p.A2512 ATS 2019 • Dallas, TX 112 SUNDAY • MAY 19